INmune Bio, Inc. Announces First Patient Dosed in Phase 2 Trial of Quellor™ for Pulmonary Complications in COVID-19 Patients

NEXT STORY
Stryker elects Giovanni Caforio to Board of Directors
PREV STORY
Pfizer and BioNTech Announce Vaccine Candidate Against COVID-19 Achieved Success in First Interim Analysis from Phase 3 Study
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Adagio Therapeutics anuncia nuevos datos que destacan el potencial de ADG20 para tratamiento y prevención de COVID-19

author_avatar
NASDAQ Market News

Worldwide Active Pharmaceutical Ingredient Industry to 2027 – by Product Type, Form, Manufacturer Type, Application and Region

author_avatar
NASDAQ Market News

Yamana Gold Reports Strong First Quarter 2021 Production Results and Cash Flows; Canadian Malartic and Minera Florida Post Standout Quarters; Jacobina Achieves All-Time Monthly High Production in March; Adopts Comprehensive Tailings Management Strategy at Jacobina that Includes Hydraulic Backfill; Identifies Potentially Significant Extension to East Gouldie Zone

author_avatar
NASDAQ Market News